TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26040543

Group type: EXPERIMENTAL
Intervention: Rehabilitation group (RG) - complex multi-method rehabilitation intervention including structured education, cognitive behavioral therapy (CBT), progressive individualized exercise, and peer support.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (UC) - standard post-operative care for the first 3 months after LFS.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rehabilitation group (RG) - secondary outcomes include Oswestry Disability Index (ODI) and physical function assessments (walking 50 yards, ascend/descend a flight of stairs).
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (UC) - secondary outcomes include Oswestry Disability Index (ODI) and physical function assessments (walking 50 yards, ascend/descend a flight of stairs).
Number of subjects: 50
Study: 22987601

Group type: EXPERIMENTAL
Intervention: HPV test (Hybrid Capture 2)
Number of subjects: 132298

Group type: COMPARATOR
Intervention: Pap test
Number of subjects: 132298
Study: 21087711

Group type: EXPERIMENTAL
Intervention: CRT-ON
Number of subjects: 610

Group type: COMPARATOR
Intervention: CRT-OFF
Number of subjects: 610
Study: 19138953

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 16189255

Group type: EXPERIMENTAL
Intervention: Depot estradiol, 0.2 mg/month i.m. with GH 0.05 mg/kg daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: GH alone (control group)
Number of subjects: 14
Study: 12970631

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 45
Study: 10658893

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT, n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Innovation Promotion Program (IPP, n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist control (n = 30)
Number of subjects: 90
Study: 8841871

Group type: EXPERIMENTAL
Intervention: 400 mg of allopurinol 18 hours and 400 mg of allopurinol orally 3 hours before surgery
Number of subjects: 52

Group type: COMPARATOR
Intervention: No allopurinol
Number of subjects: 52
Study: 1632701

Group type: EXPERIMENTAL
Intervention: Oral OK-432
Number of subjects: 970

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 970

Group type: COMPARATOR
Intervention: Intradermal OK-432
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Oral OK-432 with preserved spleen
Number of subjects: 970
Study: 6499513

Group type: EXPERIMENTAL
Intervention: 400 mg pivmecillinam twice-daily for 3 days
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 400 mg pivmecillinam twice-daily for 7 days
Number of subjects: 183
Study: 30817066

Group type: EXPERIMENTAL
Intervention: N8-GP 75 IU/kg Q7D
Number of subjects: 55

Group type: COMPARATOR
Intervention: N8-GP 50 IU/kg Q4D
Number of subjects: 55
Study: 28717855

Group type: EXPERIMENTAL
Intervention: Standard cisplatin and 5-fluorouracil (PF) with radiotherapy (RT)
Number of subjects: 131
Study: 24781891

Group type: EXPERIMENTAL
Intervention: Incremental cardiopulmonary exercise test (CPET)
Number of subjects: 40
Study: 24273298

Group type: EXPERIMENTAL
Intervention: Overground gait training
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Treadmill gait training
Number of subjects: 26
Study: 21340661

Group type: EXPERIMENTAL
Intervention: 0.25 mg digoxin qd for 5 days, then 0.25 mg digoxin qd plus 5 mg linagliptin qd for 6 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.25 mg digoxin qd for 11 days
Number of subjects: 20
Study: 19713201

Group type: EXPERIMENTAL
Intervention: Aldosterone escape
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: High urinary aldosterone
Number of subjects: 302

Group type: COMPARATOR
Intervention: Low aldosterone counterparts
Number of subjects: 302
Study: 16361060

Group type: EXPERIMENTAL
Intervention: Auditory Stimulation (AS) while performing Cognitive Task (CT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Heat Stimulation (HS) at 46 degrees C for 6 minutes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Auditory Stimulation (AS) and Heat Stimulation (HS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Auditory Stimulation (AS), Heat Stimulation (HS), and Cognitive Task (CT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (AS + HS)
Number of subjects: 60
Study: 12544367

Group type: EXPERIMENTAL
Intervention: Notoginseny cream
Number of subjects: 65

Group type: COMPARATOR
Intervention: Hirudoid cream (Control)
Number of subjects: 65
Study: 10787394

Group type: EXPERIMENTAL
Intervention: Acamprosate 666 mg three times/day
Number of subjects: 581

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581
Study: 8741298

Group type: EXPERIMENTAL
Intervention: Silver Lubricath Foley Catheter
Number of subjects: 12

Group type: COMPARATOR
Intervention: Silicone-coated catheter
Number of subjects: 12
Study: 1626496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Colestipol 5 g/day
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Colestipol 10 g/day
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Colestipol 15 g/day
Number of subjects: 152
Study: 6383234

Group type: EXPERIMENTAL
Intervention: Yttrium-90
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triamcinolone hexacetonide
Number of subjects: 0
Study: 31892668

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) applied to the ipsilesional motor cortex (M1) (600 pulses)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control stimulation (coil placement over the parieto-occipital vertex)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 150
Study: 29673362

Group type: EXPERIMENTAL
Intervention: Housing First intervention
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Coalition strategy
Number of subjects: 65
Study: 27852965

Group type: EXPERIMENTAL
Intervention: D-cycloserine (100 mg, 200 mg, and 400 mg for two weeks each)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 24937016

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (monthly counseling phone calls, weekly mailings with tailored and non-tailored materials, videos)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intervention (five informational handouts on weight loss)
Number of subjects: 0
Study: 22100204

Group type: EXPERIMENTAL
Intervention: 400 μg of misoprostol sublingually
Number of subjects: 530

Group type: COMPARATOR
Intervention: 10 units of oxytocin intramuscularly
Number of subjects: 530
Study: 20370840

Group type: EXPERIMENTAL
Intervention: Inhaled insulin therapy
Number of subjects: 240
Study: 17683324

Group type: EXPERIMENTAL
Intervention: Local infiltration anaesthesia
Number of subjects: 76

Group type: COMPARATOR
Intervention: No local infiltration anaesthesia
Number of subjects: 76
Study: 16221145

Group type: EXPERIMENTAL
Intervention: Regular non-invasive probe
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Microinvasive electrodes
Number of subjects: 140
Study: 12374540

Group type: EXPERIMENTAL
Intervention: rhIL-10 (20 micro g/kg) subcutaneously 3 times weekly for 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo subcutaneously 3 times weekly for 12 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: rhIL-10
Number of subjects: 28
Study: 10437875

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study: 7755112

Group type: EXPERIMENTAL
Intervention: Course-based diagnostic classification system for major depression
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Course-based diagnostic classification system for dysthymia
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Course-based classification system for major depression
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Interrater reliability for six course of illness specifiers
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Current or lifetime major depression or dysthymia
Number of subjects: 524
Study: 2106162

Group type: EXPERIMENTAL
Intervention: Ifosfamide 2 g/m2 days 1 to 4 with mesna uroprotection
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Doxorubicin, ifosfamide, dacarbazine at doses of 60, 7,500, and 900 mg/m2 respectively by continuous infusion over 72 hours
Number of subjects: 124

Group type: COMPARATOR
Intervention: Doxorubicin and dacarbazine alone
Number of subjects: 124

Group type: COMPARATOR
Intervention: Observation in the adjuvant treatment of high-grade sarcomas
Number of subjects: 124
Study: 6154838

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine + Diuretic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine + Diuretic + Vasodilator
Number of subjects: 0
Study: 31162860

Group type: EXPERIMENTAL
Intervention: Humidified oxygen therapy
Number of subjects: 188

Group type: COMPARATOR
Intervention: Non-humidified oxygen therapy
Number of subjects: 188
Study: 29089293

Group type: EXPERIMENTAL
Intervention: Incentives to both the expectant mother and her support person
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incentives to the expectant mother alone
Number of subjects: 0
Study: 25758990

Group type: EXPERIMENTAL
Intervention: IVF non‐male factor (IVF/NMF)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: ICSI non‐male factor (ICSI/NMF)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: ICSI male factor (ICSI/MF)
Number of subjects: 243
Study: 23614176

Group type: EXPERIMENTAL
Intervention: Experiential training using cross‐cultural movies and focused group discussions, 8 group sessions conducted.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 9
Study: 21295417

Group type: EXPERIMENTAL
Intervention: 0.32% DHA, 0.64% DHA, 0.96% DHA (DHA-supplemented formulas)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control (0% DHA)
Number of subjects: 181
Study: 19268506

Group type: EXPERIMENTAL
Intervention: estradiol (2mg) + trimegestone (0.5mg)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: estradiol (2mg) + dydrogesterone (10mg)
Number of subjects: 184
Study: 18393784

Group type: EXPERIMENTAL
Intervention: Randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allocation concealment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restricted randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjustment for prognostic variables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intent-to-treat approach
Number of subjects: 0
Study: 11984090

Group type: EXPERIMENTAL
Intervention: M-CH plus IPHHOI combined with surgery (M-CH1+IPHHOI group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 79
Study: 10413119

Group type: EXPERIMENTAL
Intervention: ACD (anterior cervical discectomy)
Number of subjects: 84

Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy with fusion)
Number of subjects: 84
Study: 7605521

Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotics
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Penicillinase-resistant antibiotics
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 1734
Study: 2257957

Group type: COMPARATOR
Intervention: 300 mg/day ranitidine plus placebo (group I)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: 300 mg/day ranitidine plus 50 mg/day pirenzepine (group II)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: 300 mg/day ranitidine plus 100 mg/day pirenzepine (group III)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: All groups (analgesic activity)
Number of subjects: 352
Study: 453054

Group type: EXPERIMENTAL
Intervention: Caloric requirements for weight gain
Number of subjects: 29
Study: 29674981

Group type: EXPERIMENTAL
Intervention: Collaborative care with placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Duloxetine alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Collaborative care with pain medication
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pain medication (paracetamol, COX inhibitors, pregabalin)
Number of subjects: 60
Study: 28233311

Group type: EXPERIMENTAL
Intervention: UVA-1 phototherapy at 30 J/cm2, escalated to 60 J/cm2 if hair regrowth was <75%, and further escalated to 120 J/cm2 if necessary; total of 25 sessions administered.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: UVA-1 phototherapy
Number of subjects: 22
Study: 24547881

Group type: EXPERIMENTAL
Intervention: Isotretinoin 30 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 24222837

Group type: EXPERIMENTAL
Intervention: Fast Track (FT) group
Number of subjects: 399

Group type: COMPARATOR
Intervention: Ordinary Care (OC) group
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 399
Study: 21415430

Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol combinations (remifentanil 0.8 to 1.6 ng · mL(‐1) and propofol 1.5 to 2.7 μg · mL(‐1))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol combinations (remifentanil approximately 3.0 to 4.0 ng · mL(‐1) and propofol 0.0 to 1.1 μg · mL(‐1))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol combinations
Number of subjects: 24
Study: 18362863

Group type: EXPERIMENTAL
Intervention: Sexual risk behaviors (e.g., > or =2 heterosexual partners in the past year, younger age at sexual debut)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Sexual risk behaviors (e.g., > or =2 heterosexual partners in the past year, enrolling both sex and drug network members)
Number of subjects: 658

Group type: COMPARATOR
Intervention: Condom use at last sex
Number of subjects: 658

Group type: COMPARATOR
Intervention: Substance abuse (methamphetamine use)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Overall prevalence of STIs
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: STI types
Number of subjects: 658
Study: 16608139

Group type: EXPERIMENTAL
Intervention: Liquid nutrition supplement (200 ml) once daily immediately after diagnosis of infection
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard treatment (enriched food after referral to a dietician)
Number of subjects: 34
Study: 14710063

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10450257

Group type: EXPERIMENTAL
Intervention: Nortriptyline at 80-120 ng/ml
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nortriptyline at 40-60 ng/ml
Number of subjects: 41
Study: 7558388

Group type: EXPERIMENTAL
Intervention: Medical Grade Silicone Rubber (MSR) with an oval 15 mm clamp, volume of 0.1531 +/- 0.0059 ml injected by five to six turns of the applicator handwheel.
Number of subjects: 122

Group type: COMPARATOR
Intervention: No-scalpel vasectomy (control group).
Number of subjects: 122
Study: 2328190

Group type: EXPERIMENTAL
Intervention: Dextromethorphan and mephenytoin coadministration
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Coadministration of mephenytoin and dextromethorphan
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 48
Study: 486628

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (n = 22)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 33
Study: 31812334

Group type: EXPERIMENTAL
Intervention: Project Re‐Engineered Discharge (RED) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (matched SNFs without RED intervention)
Number of subjects: 0
Study: 31774051

Group type: EXPERIMENTAL
Intervention: Earlier vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Later vaccination
Number of subjects: 0
Study: 29059426

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 980

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Tumor VEGF-A
Number of subjects: 980
Study: 26670076

Group type: EXPERIMENTAL
Intervention: Unilateral dose adjusted ovarian drilling (ULOD) using 60 Joules/cm(3) applied to the larger ovary
Number of subjects: 105

Group type: COMPARATOR
Intervention: Bilateral ovarian drilling (BLOD) with fixed doses of 1200 J
Number of subjects: 105
Study: 25141218

Group type: EXPERIMENTAL
Intervention: Laser+EX (diode laser 980 nm, 20 W, fluence 37.5 J/cm², total energy 1200 J, thrice weekly for 3 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: EX (placebo laser therapy plus daily exercises)
Number of subjects: 100
Study: 22381711

Group type: EXPERIMENTAL
Intervention: Fimasartan 60/120 mg daily
Number of subjects: 506

Group type: COMPARATOR
Intervention: Losartan 50/100 mg daily
Number of subjects: 506
Study: 20503802

Group type: EXPERIMENTAL
Intervention: Mathematical model for predicting protocol performance
Number of subjects: 0
Study: 17224031

Group type: EXPERIMENTAL
Intervention: Test group: primary galvanic caps fabricated on implant abutments with a secondary cast noble alloy superstructure luted with resin cement (Nimetic Cem)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group: prefabricated burn-out caps used for casting the metal frameworks, cemented with resin cement (Panavia 21)
Number of subjects: 50
Study: 15617592

Group type: EXPERIMENTAL
Intervention: Simple decompression (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Anterior deep submuscular transposition (Group B)
Number of subjects: 70
Study: 12518488

Group type: EXPERIMENTAL
Intervention: Crest SpinBrush Pro (experimental battery-powered toothbrush)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Colgate Navigator (control manual toothbrush)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Oral‐B CrossAction (control manual toothbrush)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Oral‐B CrossAction
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Crest SpinBrush Pro
Number of subjects: 127
Study: 9876347

Group type: EXPERIMENTAL
Intervention: hGH treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment
Number of subjects: 8
Study: 7625363

Group type: EXPERIMENTAL
Intervention: Low-fat diet (24% fat)
Number of subjects: 105

Group type: COMPARATOR
Intervention: High-fat diet (46% fat)
Number of subjects: 105
Study: 30307818

Group type: EXPERIMENTAL
Intervention: Isocapnic inspiratory pressure-threshold loading (PTL) to task failure followed by a constant load submaximal time-to-exhaustion (TTE) exercise test at 85% of the predetermined peak work rate.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control condition (no prior induced DF).
Number of subjects: 18
Study: 27188702

Group type: EXPERIMENTAL
Intervention: Intratympanic OTO‐201
Number of subjects: 532

Group type: COMPARATOR
Intervention: Sham (tympanostomy tubes alone)
Number of subjects: 532
Study: 26286684

Group type: EXPERIMENTAL
Intervention: Positive focussing on treatment information
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Negative focussing on treatment information
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Mixed aspects focussing on treatment information
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Irrelevant information focussing
Number of subjects: 146
Study: 21859748

Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle modification (TLM) program for 6 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group maintaining usual lifestyle behaviors
Number of subjects: 52
Study: 21364149

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (Cypher group)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (Taxus group)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (Endeavor group)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Endeavor stent
Number of subjects: 226
Study: 19805650

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 2650

Group type: EXPERIMENTAL
Intervention: Primary outcome event (composite of nonfatal myocardial infarction, nonfatal ischemic stroke, major amputation, and cardiovascular death)
Number of subjects: 2650
Study: 16886933

Group type: EXPERIMENTAL
Intervention: Migraine without aura (MoA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Migraine with aura (MA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 15248886

Group type: EXPERIMENTAL
Intervention: Delayed-immediate implant placement (Im)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Delayed single-tooth implant placement (De)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall implant treatment satisfaction (both groups)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Prosthetic procedures
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Assessment of implant surgery
Number of subjects: 46
Study: 11740133

Group type: EXPERIMENTAL
Intervention: Thyroxine therapy (mean dose 136 +/‐ 22 microg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 12
Study: 9237937

Group type: EXPERIMENTAL
Intervention: 125 mg of ferrous gluconate (15 mg elemental iron) plus multivitamins
Number of subjects: 349

Group type: COMPARATOR
Intervention: Multivitamins
Number of subjects: 349
Study: 8479488

Group type: EXPERIMENTAL
Intervention: Dapsone (50 mg per day) plus pyrimethamine (50 mg per week)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Aerosolized pentamidine (300 mg per month)
Number of subjects: 349
Study: 2879489

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30789059

Group type: EXPERIMENTAL
Intervention: ACT‐Adjust (n=10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Befriending Therapy (n=9)
Number of subjects: 19
Study: 30567595

Group type: EXPERIMENTAL
Intervention: Riociguat (1.0‐2.5 mg tid)
Number of subjects: 71
Study: 27688786

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prednisone (PDN)
Number of subjects: 9
Study: 25035080

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg) for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0